Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
UroGen Pharma announced positive top-line results from the New York based-company’s Phase III OLYMPUS clinical trial that evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer.
Sage Therapeutics’ postpartum depression oral treatment met the main goal of reducing the condition’s symptoms versus a placebo in a late-stage study, sending the drugmaker’s shares up 33 percent.
PwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.
Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.
Here is a look at BioSpace’s top 10 stories of 2018.
AstraZeneca released positive data from two clinical trials of roxadustat in anemia and of the company’s study of Lynparza in ovarian cancer.
Supernus Pharmaceuticals Inc.’s experimental drug SPN-812 for attention deficit hyperactivity disorder met the main goal in a late-stage trial on adolescents.
Eli Lilly and Co. said the company’s psoriatic arthritis (PsA) drug Taltz was found to be more effective than the world’s best-selling prescription medicine, AbbVie Inc.’s Humira, in a late-stage study.
Evofem Biosciences shares rose 38 percent after the company’s birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.